Amylyx Pharmaceuticals (NASDAQ: AMLX) has seen its stock surge over 140% in the past year, driven by advancements in its drug pipeline, particularly the completion of full enrollment in its Phase 3 trial for Avexitide, a treatment for post-bariatric hypoglycemia. With topline results expected in Q3 2026, the outcome is crucial for the stock’s short-term trajectory. However, the company’s focus on niche markets, such as rare diseases and metabolic conditions, raises questions about its long-term growth potential.

The market’s reaction to Amylyx’s progress has been mixed, with a consensus price target of $23 suggesting a 60% upside from recent levels. Yet, the stock is grappling with a 15% short interest, reflecting investor caution amid its lack of profitability and revenue generation. Comparatively, the biotech sector remains volatile, as highlighted by Regeneron’s recent Phase 3 trial setback, underscoring the inherent risks in clinical-stage investments.

For investors considering a position in AMLX, a staggered investment approach could mitigate risks while allowing for capitalizing on potential milestones. The upcoming data releases will be pivotal in determining if the stock can sustain its upward momentum.

Source: marketbeat.com